These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
710 related articles for article (PubMed ID: 21883864)
1. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864 [TBL] [Abstract][Full Text] [Related]
2. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival]. Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767 [No Abstract] [Full Text] [Related]
4. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. Heng DY; Xie W; Regan MM; Warren MA; Golshayan AR; Sahi C; Eigl BJ; Ruether JD; Cheng T; North S; Venner P; Knox JJ; Chi KN; Kollmannsberger C; McDermott DF; Oh WK; Atkins MB; Bukowski RM; Rini BI; Choueiri TK J Clin Oncol; 2009 Dec; 27(34):5794-9. PubMed ID: 19826129 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858 [TBL] [Abstract][Full Text] [Related]
6. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317 [TBL] [Abstract][Full Text] [Related]
7. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α. Tsimafeyeu I; Zart JS; Chung B BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142 [TBL] [Abstract][Full Text] [Related]
8. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias. Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657 [TBL] [Abstract][Full Text] [Related]
9. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. Iacovelli R; Lanoy E; Albiges L; Escudier B BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948 [TBL] [Abstract][Full Text] [Related]
10. Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors. Zhang HL; Sheng XN; Li XS; Wang HK; Chi ZH; He ZS; Ye DW; Guo J BMC Cancer; 2017 Jan; 17(1):16. PubMed ID: 28056874 [TBL] [Abstract][Full Text] [Related]
11. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U Oncology; 2009; 76(5):350-4. PubMed ID: 19321976 [TBL] [Abstract][Full Text] [Related]
12. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety. Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758 [TBL] [Abstract][Full Text] [Related]
13. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence. Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883 [TBL] [Abstract][Full Text] [Related]
14. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis. Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044 [TBL] [Abstract][Full Text] [Related]
15. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Grünwald V; Lin X; Kalanovic D; Simantov R Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653 [TBL] [Abstract][Full Text] [Related]
17. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. Herrmann E; Marschner N; Grimm MO; Ohlmann CH; Hutzschenreuter U; Overkamp F; Groschek M; Blumenstengel K; Pühse G; Steiner T World J Urol; 2011 Jun; 29(3):361-6. PubMed ID: 21461939 [TBL] [Abstract][Full Text] [Related]
18. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133 [TBL] [Abstract][Full Text] [Related]
19. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Khan G; Golshayan A; Elson P; Wood L; Garcia J; Bukowski R; Rini B Ann Oncol; 2010 Aug; 21(8):1618-1622. PubMed ID: 20089567 [TBL] [Abstract][Full Text] [Related]
20. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]